ConductScience.org, home

Paper39614036

Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions.

Vikal A and 6 others. Drug Deliv Transl Res, 2025. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions. Papers, record 39614036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39614036

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions.
PubMed
Journal
Drug Deliv Transl Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
5.12, provisional
iCite
Revised in PubMed
2026-11-03
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vikal AAkash
2Maurya RRashmi
3Patel BBBrij Bihari
4Sharma RRajeev
5Patel PPreeti
6Patil UKUmesh K
7Das Kurmi BBalakhttps://orcid.org/0000-0001-8470-6622

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
ProteolysisMajor topic
Antineoplastic AgentsMajor topic
Humans
Animals
Clinical Trials as Topic
Proteolysis Targeting Chimera

Source PubMed

Download CSV of topics

References174

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135410300Proteolysis-targeting chimeras (PROTACs) in cancer therapy.Mol Cancer2022https://conductscience.org/library/papers/35410300PubMed
232297626A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.Chem Commun (Camb)2020https://conductscience.org/library/papers/32297626PubMed
331902710Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).Bioorg Med Chem Lett2020https://conductscience.org/library/papers/31902710PubMed
433275901Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.Cell2020https://conductscience.org/library/papers/33275901PubMed
531047748Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.Bioorg Med Chem Lett2019https://conductscience.org/library/papers/31047748PubMed
630012605Delineating the role of cooperativity in the design of potent PROTACs for BTK.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/30012605PubMed
735464214Rigidity and Flexibility in Rotaxanes and Their Relatives; On Being Stubborn and Easy-Going.Front Chem2022https://conductscience.org/library/papers/35464214PubMed
814749129Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.Cancer Cell2004https://conductscience.org/library/papers/14749129PubMed
933143537E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.SLAS Discov2021https://conductscience.org/library/papers/33143537PubMed
1035755293NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion.Acta Pharm Sin B2022https://conductscience.org/library/papers/35755293PubMed
1131097984Treatment of Alzheimer's by PROTAC-Tau Protein Degradation.ACS Med Chem Lett2019https://conductscience.org/library/papers/31097984PubMed
1231660436Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs.ACS Cent Sci2019https://conductscience.org/library/papers/31660436PubMed
1323614556Reversible photocontrol of biological systems by the incorporation of molecular photoswitches.Chem Rev2013https://conductscience.org/library/papers/23614556PubMed
148902388Oncogenic proteins as tumor antigens.Curr Opin Immunol1996https://conductscience.org/library/papers/8902388PubMed
1535066101Wnt/β-catenin signaling in colorectal cancer: Is therapeutic targeting even possible?Biochimie2022https://conductscience.org/library/papers/35066101PubMed
1634203106Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors.Cancers (Basel)2021https://conductscience.org/library/papers/34203106PubMed
1726564077Von Hippel-Lindau disease.Handb Clin Neurol2015https://conductscience.org/library/papers/26564077PubMed
1820043028Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.Nat Rev Drug Discov2010https://conductscience.org/library/papers/20043028PubMed
1936733714E3 ligase ligand optimization of Clinical PROTACs.Front Chem2023https://conductscience.org/library/papers/36733714PubMed
2030742854Light-triggered release of photocaged therapeutics - Where are we now?J Control Release2019https://conductscience.org/library/papers/30742854PubMed

See all 174 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42415161Fluorinated Aminopiperidones as Non-Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation.ChemMedChem2026https://conductscience.org/library/papers/42415161PubMed
42244865Research progress and future perspectives in proteolysis-targeting chimeras.Front Pharmacol2026https://conductscience.org/library/papers/42244865PubMed
42187721Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology.Biology (Basel)2026https://conductscience.org/library/papers/42187721PubMed
42050258The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases.Cell Mol Life Sci2026https://conductscience.org/library/papers/42050258PubMed
41821623Protacs in oral cancer: degrading oncogenic drivers for next-generation therapy.Front Oral Health2026https://conductscience.org/library/papers/41821623PubMed
41799503Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncol Res2026https://conductscience.org/library/papers/41799503PubMed
41750393Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms.Biomolecules2026https://conductscience.org/library/papers/41750393PubMed
41362117Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation.Drug Dev Res2025https://conductscience.org/library/papers/41362117PubMed
41174249Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.EMBO J2025https://conductscience.org/library/papers/41174249PubMed
40874151Breaking the oncogenic alliance: advances in disrupting the MTDH-SND1 complex for cancer therapy.RSC Adv2025https://conductscience.org/library/papers/40874151PubMed
40871058Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.Pharmaceutics2025https://conductscience.org/library/papers/40871058PubMed
40839238Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α-p300/CBP alliance.Invest New Drugs2025https://conductscience.org/library/papers/40839238PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39614036

GET https://conductscience.org/api/papers/v1/39614036/references?page=2